Mansukani Sharad 4

What Happened

• Mansukani Sharad, a director of agilon health, was granted 2,133 restricted stock units (reported as 2,133 shares) on June 2, 2026. The award was recorded at $0.00 per share (an equity award, not a cash purchase), so no cash changed hands at grant.
• These RSUs vest in full on June 2, 2027, subject to continued service as a director, meaning the shares are not yet freely tradable and do not reflect an immediate market sale or purchase.

Key Details

• Transaction date: 2026-06-02; Transaction type: Award/Grant (code A); price reported: $0.00.
• Vesting: RSUs vest in full on 2027-06-02, contingent on continued board service (Footnote F1).
• Post-transaction ownership: Filing notes beneficial ownership figures (not specified in the excerpt) reflect a 1-for-25 reverse stock split effective March 30, 2026, and include restricted stock units (Footnotes F2, F3).
• Filing timeliness: Form 4 filed 2026-06-04 for a 2026-06-02 transaction — filed within the typical two-business-day window (timely).

Context

• This was an equity award (RSUs) rather than an open-market purchase or sale. RSU grants are compensation and typically vest over time; they do not indicate an immediate trading signal until vested shares are sold.
• The reverse 1-for-25 split noted in the filing affects reported share counts across filings and should be considered when comparing past insider transactions.